Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-671-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013-10-02 to 2014-08-27
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted 27 Jul 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3500 (Preliminary Developmental Toxicity Screen)
- Version / remarks:
- adopted Jul 2000
- Qualifier:
- according to guideline
- Guideline:
- other: Commission Regulation (EC) No. 440/2008, L 142, Appendix Part B
- Version / remarks:
- adopted 30 May 2008
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Reaction mass of 1,1'-(2,2,4-trimethylhexane-1,6-diyl)bis-1H-pyrrole-2,5-dione and 1,1'-(2,4,4-trimethylhexane-1,6-diyl)bis-1H-pyrrole-2,5-dione
- EC Number:
- 915-671-3
- Molecular formula:
- C17H22N2O4
- IUPAC Name:
- Reaction mass of 1,1'-(2,2,4-trimethylhexane-1,6-diyl)bis-1H-pyrrole-2,5-dione and 1,1'-(2,4,4-trimethylhexane-1,6-diyl)bis-1H-pyrrole-2,5-dione
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, 97633 Sulzfeld, Germany
- Age at study initiation: 10-11 weeks (males) and 10-11 weeks (females)
- Weight at study initiation: 270 - 318 g (males) and 184 - 219 g (females)
- Housing: individually in IVC cages (except during the mating period when one female was paired with one male), type III H, polysulphone cages on Altromin saw fibre bedding
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: at least 5 days under laboratory conditions
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG 400
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was ground to a fine powder and was weighed into a tared plastic vial on a suitable precision balance and the vehicle was added to give the appropriate final concentration of the test item. The formulation was mixed thoroughly using a homogenizer. The test item formulation was prepared once a week and stored at ambient temperature. Every day 20 minutes before the dose administration the formulation was kept on a magnetic stirrer to ensure the homogeneity. Homogeneity of the test item in the vehicle was also maintained by keeping the prepared suspension on a magnetic stirrer during dose administration.
VEHICLE
- Concentration in vehicle: 3, 6 and 12 mg/mL
- Amount of vehicle: 5 mL/kg bw/day
- Lot/batch no.: 1101401034 - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: until mating was confirmed
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of gestation
- After successful mating each pregnant female was caged: individually in IVC cages type III H polysulphone cages on Altromin saw fibre bedding - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration analysis of formulation samples was determined in study week 1, 2, 4 and 7 for all dose groups. The mean recoveries observed at 15, 30 and 60 mg/kg bw/day were 105.4%, 97.0% and 97.5% of the nominal concentration, respectively.
Stability of formulation samples was investigated for the 15 and 60 mg/kg bw/day dose groups. After storage at room temperature for 7 days recovery compared to starting value was between 93.6% and 106.7%.
Homogeneity of formulation samples was determined in study week 1 and 7 for formulations of the dose groups 15 and 60 mg/kg bw/day. The mean recovery observed for the 15 mg/kg bw/day dose group was between 91.9% and 93.0% of the nominal value and between 90.4% and 94.5% of the nominal value for the 60 mg/kg bw/day dose group. The coefficients of variation of the different sampling locations (top, middle and bottom) were between 1.3% and 2.4% at 15 mg/kg bw/day and between 1.2% and 1.7% at 60 mg/kg bw/day. - Duration of treatment / exposure:
- The females were treated with the test item formulation or vehicle 7 days per week for a period of 54 days, i.e. during 14 days of pre-mating and maximum 14 days of mating, during the gestation period and up to post-natal day 3.
Males were dosed during 14 days of pre-mating and maximum 14 days of mating. After the mating period until the minimum total dosing period of 28 days were completed. - Frequency of treatment:
- daily, 7 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 30 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 60 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The doses were selected on the basis of data from a dose range-finding study, and a 28-day study started 3 weeks prior to this study in which mortality was observed at the dose levels 125 and 100 mg/kg bw/day.
Examinations
- Parental animals: Observations and examinations:
- OBSERVATIONS: Yes
- Time schedule: The animals were checked once daily for clinical signs and twice daily for morbidity and mortality, except for weekends and public holidays when observations were made once daily.
- Observations included: Spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in skin and fur, eyes and mucous membranes (salivation, discharge), piloerection and pupil size. In addition, changes in gait, posture, response to handling as well as the presence of clonic or tonic movements, stereotypes, difficult or prolonged parturition or bizarre behaviour were recorded.
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: The body weight was recorded once before the assignment to the experimental groups, on the first day of administration and weekly during the treatment period as well as at the end of the study. During pregnancy, females were weighed on gestation days (GD) 0, 7, 14 and 20 and within 24 hours of parturition (day 0 post-partum) as well as day 4 post-partum along with pups. The animal prematurely sacrificed was weighed prior to the sacrifice.
FOOD CONSUMPTION: Yes
- Time schedule for food consumption: Food consumption was measured weekly on the same days of the body weight measurements after the beginning of the dose administration. Food consumption was not measured during the mating period in males and females and the post-mating period in males.
FOOD EFFICIENCY: No - Sperm parameters (parental animals):
- Parameters examined in male parental generation P0: testis weight and epididymis weight.
For the testes a detailed qualitative examination was made, taking into account the tubular stages of the spermatogenic cycle at evaluation of additional hematoxylin-PAS stained slides. - Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in the F1 offspring: number and sex of pups, stillbirths, live births, runts and the presence of gross anomalies. Live pups were counted and sexed and litters weighed within 24 h of parturition (day 0 post-partum) and on day 4 post-partum. Live pups were identified by the tattoo mark on the paw. In addition to the observations of parent animals, any abnormal behaviour of the offspring was recorded.
GROSS EXAMINATION OF DEAD PUPS: Yes, the dead pups and pups sacrificed on day 4 post partum were carefully examined externally for gross abnormalities.
ASSESSMENT OF DEVELOPMENTAL NEUROTOXICITY: No
ASSESSMENT OF DEVELOPMENTAL IMMUNOTOXICITY: No - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All male animals were sacrificed after the completion of the mating period (total dosing period: 28 days) on study Day 29.
- Maternal animals: Females which delivered were sacrificed on post-natal day 4 (PND 4).
- Non-pregnant females were sacrificed on study Day 26 from the day of evidence of mating.
GROSS NECROPSY
All animals were subjected to a detailed gross necropsy which included careful examination of the external surface of the body, all orifices and the cranial, thoracic and abdominal cavities and their contents. Special attention was paid to the organs of the reproductive system. The number of implantation sites and corpora lutea was recorded for each parental female. The ovaries, uterus with cervix, vagina, testes, epididymides, accessory sex organs (prostate, seminal vesicles with coagulating glands as a whole), and all organs showing macroscopic lesions of all adult animals were preserved in 10% neutral buffered formalin, except for testes and epididymides which were fixed in modified Davidson’s Solution for 24 hours and transferred to 70% ethanol.
ORGAN WEIGHTS
The following organs were weighed for all selected animals at necropsy: brain, stomach, small and large intestines (including Peyer's patches), liver, thymus, spleen, ovaries, uterus with cervix, lung, urinary bladder, lymph nodes (mesenteric and axillary), trachea, kidneys, adrenal glands, heart, testes, epididymides and all gross lesions.
HISTOPATHOLOGY
Tissues / Organs examined by light microscopy were: epididymides, ovaries, prostate gland, seminal vesicles with coagulating glands, testes, uterus with cervix, vagina and all gross lesions. - Postmortem examinations (offspring):
- SACRIFICE:
- All surviving pups were sacrificed by decapitation on PND 4.
GROSS NECROPSY:
- Dead pups and pups sacrificed on day 4 post-partum were carefully examined externally for gross abnormalities.
HISTOPATHOLOGY / ORGAN WEIGHTS: not performed
- Statistics:
- A statistical assessment of the results of the body weight, food consumption, parameters of absolute and relative organ weights were performed for each gender by comparing values of dosed with control animals of the main groups using a one-way ANOVA and a post-hoc Dunnett Test. These statistics were performed with GraphPad Prism V.6.01 software (p<0.05 was considered as statistically significant).
- Reproductive indices:
- Copulation Index (%) = (No. of rats copulated / No. of pairs) X 100%
Fertility Index (%) = (No. of females pregnant / No. of females copulated) X 100%
Delivery Index (%) = (No. of dams with live new borns / No. of pregnant dams) X 100% - Offspring viability indices:
- Viability Index (%) = (No. of live offspring at day 4 / No. of live offspring at birth) X 100%
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no clinical signs that were considered to be an adverse effect of treatment. Clinical signs were observed in all treatment and control groups and comprised slight to moderate and/ or severe diarrhea, piloerection, salivation and/ or nasal discharge in both sexes. The incidences of diarrhea and salivation in males and nasal discharge and salivation in females were similar in control animals. However, the incidences of moving the bedding, abnormal breathing, piloerection and nasal discharge in males, and moving the bedding, abnormal breathing and diarrhea in females were observed at a higher frequency in test item-treated animals, with an increased severity at higher doses. Abnormal breathing, piloerection and nasal discharge in males and/ or females were transient. The observations were made more frequently in the second half of the study (after mating) and considered to be treatment-related. Incidences of moving the bedding and salivation were considered to be due to discomfort caused to the animals during the test item treatment. Other findings such as alopecia, eschar and slightly discolored green feces in single isolated animals at 30 and 60 mg/kg bw/day were considered to be incidental. For details please refer to Table no. 1 under "Any other information on results incl. tables".
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 30 mg/kg bw/day: 1/10 females died on gestation day 5, treatment-related, the cause was considered to be accidental influx into the respiratory tract of the test substance but not due to systemic toxicity.
60 mg/kg bw/day: 1/10 females was killed for ethical reasons on PND 2, treatment-related, the cause was considered to be accidental influx into the respiratory tract of the test substance but not due to systemic toxicity. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- 30 mg/kg bw/day: Statistically significant decrease in body weight gain in females in the first week of gestation, transient finding, non-adverse.
60 mg/kg bw/day: Decreased mean body weight in males after 2 weeks of treatment (-7 to -5% of control), statistically significant from week 3 onwards, treatment-related, considered to be a result of local irritative effects of the test item in the forestomach.
(For details please refer to Table no. 2 under "Any other information on results incl. tables"). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- 60 mg/kg bw/day: statistically significantly decreased in males during the pre-mating period, in line with reduced body weight gain, considered to be a result of local irritative effects of the test item in the forestomach; slightly (statistically not significantly) decreased in females after 2 weeks of treatment, during the last week of gestation and during the lactation period, observations in females were within the normal biological variation.
(For details please refer to Table no. 3 under "Any other information on results incl. tables"). - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no test item-related abnormalities noted in surviving animals. 1/10 females at 30 mg/kg bw/day and 1/10 females at 60 mg/kg bw/day that died during the treatment period or were killed in extremis showed necrotising inflammation of the trachea or nose and findings in the lungs (flocculent and fluid contents in the bronchi, bronchiole and alveolar space and tracheal mucosal epithelial hypertrophy and alveolitis at/around broncheolar/alveolar duct area of the lung) which indicated an accidental regurgitation/aspiration of the test item. Both females had histopathological findings in the forestomach. Epithelial squamous hyperplasia, hyperkeratosis, parakeratosis were noted in both animals, whereas submucosal edema and dyskeratosis were recorded only in the dead female of the high dose group. The findings were attributed to local irritation caused by the test substance but not to systemic toxicity. Both animals showed thymic atrophy and/or splenic lymphoid atrophy and adrenocortical diffuse hypertrophy, which were related to stress. Sertoli cell vacuolisation and/or spermatid retention were recorded at minimal severity in 4/10, 0/10, 1/10 and 2/10 and in 1/10, 0/10, 1/10 and 0/10 males at 0, 15, 30 and 60 mg/kg bw/day. As no dose relation in incidence and severity was evident, the findings were considered to be unrelated to treatment. The remainder of findings was within the range of normal background lesions which may be recorded in animals of this age and strain.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Fertility indices were 70, 100, 100 and 90% at 0, 15, 30 and 60 mg/kg bw/day, respectively. The decrease in the control and high dose group was considered to be incidental.
Copulation indices were 100, 90, 90 and 100% at 0, 15, 30 and 60 mg/kg bw/day and delivery indices were 100% for all control and treatment groups.
Gestation length and pre-coital interval: There were no treatment related changes noted for the duration of precoital interval and the duration of gestation.
Number of implantation sites: There were no treatment-related findings.
Number of corpora lutea: There were no treatment-related findings.
Pre-implantation losses: There were no treatment-related findings.
Effect levels (P0)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 60 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no systemic toxicity observed
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproductive/fertility
- Effect level:
- 60 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effect observed
Target system / organ toxicity (P0)
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- 60 mg/kg bw/day: The pups of one female had cold bodies and an intact umbical cord, indicating lack of nursing behaviour of the female. The finding was limited to a single female and was within the range of historical background data, therefore not attributed to treatment.
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- Post-implantation losses: There was in increase (statistically not significant) in the percent of post-implantation loss at 15, 30 and 60 mg/kg bw/day (3.31 ± 4.14%, 6.94 ± 11.14%, 14.42 ± 23.93% and 10.56 ± 7.50% at 0, 15, 30 and 60 mg/kg bw/day, respectively). The values were within those of historical control data and without dose relation, therefore the finding was considered to be unrelated to treatment.
Viability indices were 100, 100, 100 and 87.50% at 0, 15, 30 and 60 mg/kg bw/day. The decrease at 60 mg/kg bw/day was within the range of historical control data and thus considered to be incidental.
Number of still births: At 60 mg/kg bw/day a slight increase in the number of stillbirths was noted. The finding was limited to 2 isolated females and within the range of historical control data and therefore considered to be not treatment-related
Number of live pups on PND 0 and 4: A slight decrease in the number of live pups was noted at 60 mg/kg bw/day on PND 4. The finding was attributed to one female of which all pups were found dead between PND 1-2 and not considered treatment-related.
Number of male and female pups on PND 0 and 4: A slight decrease in the total number of male pups was noted at 60 mg/kg bw/day on PND 4. The finding was attributed to one female wherein all pups were found dead between PND 1-2. The observation was within the historical control range and not considered treatment-related. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was a very slight decrease in male litter weight on PND 0 and 4. This was due to a slightly lower number of male pups at 60 mg/kg bw/day, which was compensated by a slightly higher number of female pups.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Anogenital distance (AGD):
- not examined
- Nipple retention in male pups:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- 0 mg/kg bw/day: one pup of one female had a discoloured dark snout, not treatment-related.
15 mg/kg bw/day: one pup of one female had a discoloured dark snout, not treatment-related.
30 mg/kg bw/day: one pup of one female had a discoloured dark snout, not treatment-related.
60 mg/kg bw/day: one pup of one female had a discoloured dark snout, one pup of one female had a discoloured dark head, one pup of one female had a discoloured dark right hindleg, all pups of one female showed hypothermia and had an intact umbical cord, not treatment-related. - Histopathological findings:
- no effects observed
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Generation:
- F1
- Effect level:
- 60 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
Target system / organ toxicity (F1)
- Critical effects observed:
- no
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Table 1: Clinical signs in parental animals (P0)
Dose group [mg{kg bw/day] | 0 | 15 | 30 | 60 |
Clinical Finding in males | ||||
Total number of animals examined | 10 | 10 | 10 | 10 |
Alopecia on flank, thigh and forepaws | - | 1 | - | - |
Crust on left ear | - | - | - | 1 |
Moderate abnormal breathing | - | - | 1 | 2 |
Moderate diarrhoea | 7 | 7 | 8 | 7 |
Moderate piloerection | - | - | 2 | 4 |
Moderate salivation | - | 5 | 10 | 10 |
Moving the bedding | - | 8 | 10 | 10 |
Nasal discharge (plain/ red) | - | - | 2 | 4 |
Severe abnormal breathing | - | - | 1 | 2 |
Severe diarrhoea | - | 1 | - | - |
Severe piloerection | - | - | - | 2 |
Severe salivation | - | 3 | 6 | 8 |
Slight abnormal breathing | - | 2 | 3 | 2 |
Slight diarrhoea | 7 | 6 | 5 | 7 |
Slight piloerection | - | 1 | 6 | 4 |
Slight salivation | 2 | 5 | 7 | 10 |
slightly discoloured faeces (green) | - | - | - | 1 |
Clinical Finding in females | ||||
Total number of animals examined | 10 | 10 | 10 | 10 |
Alopecia on head | - | - | - | 1 |
Alopecia on left hind flank | - | 1 | - | - |
Crust on eye | - | - | 1 | - |
Moderate abnormal breathing | - | - | - | 5 |
Moderate diarrhoea | - | 2 | 5 | 7 |
Moderate piloerection | 1 | - | 1 | 4 |
Moderate salivation | 4 | 4 | 8 | 10 |
Moderate piloerection | - | 1 | - | - |
Moving the bedding | - | 7 | 10 | 10 |
Nasal discharge (red) | 2 | 3 | - | 2 |
Severe abnormal breathing | - | - | - | 1 |
Severe diarrhoea | - | 1 | 1 | 2 |
Severe piloerection | - | - | - | 2 |
Severe salivation | - | 3 | 6 | 8 |
Slight abnormal breathing | 1 | - | 2 | 4 |
Slight diarrhoea | - | 2 | 3 | - |
Slight piloerection | - | - | 6 | 7 |
Slight salivation | 5 | 5 | 6 | 10 |
Weight loss | - | - | - | 1 |
Table 2: Body weight development in parental males during treatment
Dose [mg/kg bw/day] |
Males | Females | ||||||||||||||
Premating | Mating and Postmating | Terminal Sacrifice | Premating | Gestation | Lactation | |||||||||||
Day 1 | Day 7 | Day 14 | Day 7 | Day 14 | Day 1 | Day 7 | Day 14 | Day 0 | Day 7 | Day 14 | Day 20 | Day 0 | Day 4 | |||
0 | Mean | 288 | 310 | 328.8 | 341 | 352.2 | 356.7 | 199.3 | 201.9 | 210.7 | 212.43 | 237.57 | 264.57 | 316.14 | 244.14 | 254.29 |
SD | 10.81 | 10.13 | 13.69 | 14.73 | 19.98 | 18.77 | 8.63 | 9.1 | 10.97 | 9.36 | 9.34 | 10.13 | 12.29 | 21.39 | 19.36 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 7 | 7 | 7 | 7 | 7 | |
15 | Mean | 287.9 | 308.9 | 326.7 | 339.3 | 349.7 | 352.3 | 199.5 | 209.9 | 209.4 | 213.67 | 238.89 | 270.67 | 331.11 | 247.3 | 256.8 |
SD | 11.47 | 12.34 | 15.7 | 16.42 | 19.36 | 19.76 | 8.86 | 11.32 | 7.38 | 7.98 | 8.64 | 11.32 | 16.24 | 20.63 | 15.01 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | |
% | 100 | 100 | 99 | 100 | 99 | 99 | 100.1 | 104 | 99.4 | 100.6 | 100.6 | 102.3 | 104.7 | 101.3 | 101 | |
30 | Mean | 288.8 | 310.8 | 330.9 | 341.7 | 352.6 | 355.9 | 199.8 | 206 | 208.7 | 212 | 231.5 | 259.25 | 310.75 | 247.67 | 248.78 |
SD | 12.35 | 13.45 | 11.06 | 13.87 | 13.5 | 13.67 | 8.5 | 9.03 | 8.59 | 9.6 | 12.11 | 15.04 | 27.07 | 17.8 | 16.85 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 8 | 8 | 8 | 9 | 9 | |
% | 100 | 100 | 101 | 100 | 98 | 100 | 100.3 | 102 | 99.1 | 99.8 | 97.4 | 98 | 98.3 | 101.4 | 97.8 | |
60 | Mean | 290.1 | 299.3 | 313.10* | 323.90* | 327.40* | 331.20* | 200.8 | 206.8 | 217.2 | 213.33 | 232.22 | 261.78 | 313.89 | 246.56 | 248.38 |
SD | 12.01 | 13.04 | 15.26 | 13.76 | 21.49 | 20.63 | 9.1 | 9.39 | 12.14 | 6.44 | 9.16 | 10.08 | 11.67 | 12.79 | 8.83 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 8 | |
% | 101 | 97 | 95 | 95 | 93 | 93 | 100.8 | 102.4 | 103.1 | 100.4 | 97.7 | 98.9 | 99.3 | 101 | 97.7 |
Table 3: Food consumption data in parental males and females
Dose [mg/kg bw/day] |
Premating | Premating | Gestation | Lactation | |||||
Day 1-7 | Day 7-14 | Day 1-7 | Day 7-14 | Day 0-7 | Day 7-14 | Day 14-20 | Day 0-4 | ||
0 | Mean | 155.7 | 180.9 | 98.9 | 116.7 | 130.57 | 149.71 | 140.86 | 104 |
SD | 12.97 | 9.76 | 8.97 | 12.44 | 18.89 | 12.84 | 15.39 | 17.39 | |
N | 10 | 10 | 10 | 10 | 7 | 7 | 7 | 7 | |
15 | Mean | 150.4 | 176.1 | 96.7 | 119 | 138.56 | 156.11 | 144.22 | 116.6 |
SD | 10.63 | 10.9 | 9.6 | 8.47 | 45.35 | 14.16 | 16.95 | 18.65 | |
N | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 10 | |
30 | Mean | 142.2 | 178.44 | 102 | 109.1 | 134.75 | 141.88 | 132 | 95.56 |
SD | 6.27 | 7.4 | 15.3 | 16.96 | 24.69 | 9.03 | 8.77 | 25.09 | |
N | 10 | 9 | 10 | 10 | 8 | 8 | 8 | 9 | |
60 | Mean | 116.20*** | 154.50** | 96.3 | 80.29* | 169.44 | 148.33 | 127.78 | 96.13 |
SD | 18.47 | 24.9 | 7.76 | 48.26 | 34 | 42.18 | 34.86 | 32.67 | |
N | 10 | 10 | 10 | 7 | 9 | 9 | 9 | 8 |
Table 4: Absolute and relative organ weights in parental animals after treatment
Dose [mg/kg bw/day] |
Body weight (g) | Males | Females | |||||||||||||
Absolute organ weights | Relative organ weights | Absolute organ weights | Relative organ weights | |||||||||||||
Prostate# | Testes | Epididymis | Prostate# | Ovaries | Uterus with Cervix | Ovaries | Uterus with Cervix | |||||||||
Testes | Epididymis | left | right | total | left | right | total | |||||||||
0 | Mean | 356.7 | 3.582 | 1.154 | 2.097 | 1.005 | 0.323 | 0.588 | 0.0528 | 0.05 | 0.1028 | 0.941 | 0.0208 | 0.0196 | 0.0404 | 0.375 |
SD | 18.77 | 0.398 | 0.116 | 0.1932 | 0.106 | 0.025 | 0.051 | 0.0118 | 0.012 | 0.0235 | 0.12 | 0.0038 | 0.0038 | 0.0075 | 0.072 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | |
15 | Mean | 352.3 | 3.717 | 1.203 | 2.1767 | 1.056 | 0.342 | 0.619 | 0.058 | 0.0552 | 0.1132 | 0.913 | 0.0228 | 0.0216 | 0.0444 | 0.357 |
SD | 19.76 | 0.307 | 0.072 | 0.237 | 0.08 | 0.02 | 0.07 | 0.0059 | 0.0096 | 0.0103 | 0.136 | 0.003 | 0.0034 | 0.0043 | 0.044 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
% | 98.8 | 103.8 | 104.2 | 103.8 | 105.1 | 105.7 | 105.2 | 109.9 | 110.3 | 110.1 | 97 | 109.9 | 109.9 | 109.9 | 95.1 | |
30 | Mean | 355.9 | 3.615 | 1.207 | 2.1044 | 1.016 | 0.339 | 0.592 | 0.0537 | 0.0463 | 0.1 | 0.94 | 0.0217 | 0.0187 | 0.0403 | 0.378 |
SD | 13.67 | 0.253 | 0.092 | 0.224 | 0.064 | 0.024 | 0.061 | 0.0084 | 0.0051 | 0.0101 | 0.115 | 0.0038 | 0.0022 | 0.0047 | 0.045 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | |
% | 99.8 | 100.9 | 104.6 | 100.4 | 101.1 | 104.9 | 100.6 | 101.7 | 92.6 | 97.3 | 99.8 | 104.4 | 95.1 | 99.9 | 100.9 | |
60 | Mean | 331.2 | 3.463 | 1.129 | 1.8508* | 1.046 | 0.341 | 0.559 | 0.0531 | 0.0529 | 0.106 | 0.973 | 0.0214 | 0.0213 | 0.0426 | 0.392 |
SD | 20.63 | 0.284 | 0.108 | 0.2221 | 0.063 | 0.027 | 0.065 | 0.0154 | 0.0103 | 0.0217 | 0.122 | 0.006 | 0.0036 | 0.008 | 0.048 | |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | |
% | 92.9 | 96.7 | 97.9 | 88.3 | 104.1 | 105.5 | 95.1 | 100.5 | 105.9 | 103.1 | 103.3 | 102.8 | 108.3 | 105.5 | 104.5 | |
# = including seminal vesicle and coagulating gland |
Applicant's summary and conclusion
- Conclusions:
- There was no systemic toxicity observed. Clinical signs of toxicity, changes in body weight development and food consumption, as well as any pathological findings observed were due to the local irritating effects caused by the corrosive nature of the test item. The NOAEL for both systemic toxicity and fertility of adult animals (P0, male and female) was 60 mg/kg bw/day. The NOAEL for developmental toxicity (F1) was 60 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.